secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001437749-23-020094
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris terminates AstraZeneca deal, cuts 70% workforce, explores strategic alternatives
--------------------------------------------------------------------------------

- AstraZeneca terminates R&D collaboration effective Oct 15, 2023 due to non-clinical safety findings in elarekibep toxicology study.
- Workforce reduced by ~70%; expects ~$3.4M severance costs in Q3 2023.
- Cash, equivalents, investments ~$54.9M as of June 30, 2023 (preliminary).
- Pieris hires Stifel as financial advisor to explore strategic alternatives including M&A, licensing, or sale.
- Focus shifted to advancing cinrebafusp alfa, PRS-220, PRS-400; no assurance of transaction outcome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/0001437749-23-020094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/pirs20230705_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-020094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer